Advisory Cmte. Chair Conflicts Of Interest Bar His Vote On Pfizer’s Exubera
Executive Summary
Conflicts of interest caused Nelson Watts (University of Cincinnati Bone Health) to be recused as chair of the Endocrinologic & Metabolic Drugs Advisory Committee and barred from voting during the committee's Sept. 8 review of Pfizer/Sanofi-Aventis' inhaled insulin Exubera
You may also be interested in...
Study Involvement Is Not Conflict For Advisory Cmte Members – FDA’s Temple
Conducting clinical trials for a manufacturer generally does not pose a conflict of interest risk for advisory committee members, FDA Office of Medical Policy Director Robert Temple said Aug. 23
New FDA Conflict Of Interest Policy Enacted At MT 100 Committee Meeting
FDA's new conflict-of-interest disclosure policy for advisory committee members was inaugurated at the Aug. 4 Peripheral & Central Nervous System Drugs Advisory Committee meeting
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011